Urothelial Carcinoma Clinical Trials in Grand Rapids, Michigan

4 studies are recruiting for urothelial carcinoma in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. DBC-664 in Adult Patients With Solid Tumors

   DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   5 in total

   Run by

   Duboce Biopharmaceuticals, Inc.

   See if you can join NCT07705035 on ClinicalTrials.gov

2. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

3. A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

   This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanc…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The Cancer & Hematology Centers, Grand Rapids, Michigan

   Locations

   221 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04879329 on ClinicalTrials.gov

4. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov